A1: You bring up a good point: never fall in love with a stock and over-invest. And we all try to remember that.
Whether the bashers are paid or not, they are annoying. And I really can't think of one point that they have brought up recently which hasn't been covered before. I expect, and know, that most of us long terms are not spring chickens. We've been around the block a few times and don't need to be saved. About being paid bashers - don't know but if you've been with this stock for a while you know that a mint can be made by buying low and selling higher. The stock goes up and down. For that reason alone I couldn't discount paid bashers.
The thing that is annoying is that the "bashers" are forgetting that the guys working on this are world renown scientists. If it's gonna float, they are the ones who are gonna provide the buoy. Moro, Gold etal have reputations to uphold. They don't want their good names to be linked to a scam which these bashers keep implying. So what do we have? A company led by knowledgeable people, the best in their field; a product that could be the answer to cancer diagnosis and treatment; and a license agreement from the second largest pharmaceutical company in the world. Sounds like the ingredients for a successful venture so I'm betting on it. Sure beats the odds in slots.
BOCX, at this time, is the best hope we have of getting a handle on cancer. I plan to stick with it until I know for sure whether we have a hit or a miss.
News 
Market Data 
Discover 
